Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,015Revenue $M149Net Margin (%)-26.3Z-Score-1.3
Enterprise Value $M1,909EPS $-1.4Operating Margin %-7.0F-Score5
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-25.3Higher ROA y-yY
Price/Book42.410-y EBITDA Growth Rate %0Quick Ratio3.9Cash flow > EarningsN
Price/Sales9.55-y EBITDA Growth Rate %29.1Current Ratio4.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-12.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M128ROI % (ttm)-196.7Gross Margin Increase y-yY

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NKTRPRIMECAP Management 2014-03-31 Add0.04%$11.35 - $14.96
($13.16)
$ 15.6919%Add 24.29%15,534,086
NKTRPRIMECAP Management 2013-12-31 Add0.03%$8.96 - $12.56
($10.75)
$ 15.6946%Add 25.56%12,498,386
NKTRPRIMECAP Management 2013-09-30 Add0.03%$10.541 - $13.96
($12.36)
$ 15.6927%Add 31.41%9,953,856
NKTRPRIMECAP Management 2012-12-31 Reduce-0.05%$5.99 - $10.83
($8.09)
$ 15.6994%Reduce -29.07%6,469,856
NKTRJean-Marie Eveillard 2011-12-31 Sold Out -0.003%$4.22 - $5.62
($4.9)
$ 15.69220%Sold Out0
NKTRJean-Marie Eveillard 2011-09-30 Buy $4.98 - $7.65
($5.97)
$ 15.69163%New holding, 125000 sh.125,000
NKTRPRIMECAP Management 2011-03-31 Add0.02%$8.58 - $12.85
($10.43)
$ 15.6950%Add 41.43%6,128,100
NKTRPRIMECAP Management 2010-06-30 Add0.04%$11.25 - $15.58
($13.3)
$ 15.6918%Add 82.73%3,579,750
NKTRPRIMECAP Management 2010-03-31 Add0.03%$9.15 - $15.52
($12.67)
$ 15.6924%Add 106.54%1,959,000
NKTRPRIMECAP Management 2009-12-31 Add0.01%$8.07 - $9.84
($9.01)
$ 15.6974%Add 104.73%948,500
NKTRPRIMECAP Management 2009-09-30 Add0.01%$5.89 - $10.47
($7.71)
$ 15.69104%Add 210.94%463,300
NKTRPRIMECAP Management 2009-06-30 Add$5.02 - $6.94
($5.94)
$ 15.69164%Add 50.51%149,000
NKTRGeorge Soros 2008-03-31 Sold Out -0.07%$6.27 - $7.29
($6.8)
$ 15.69131%Sold Out0
NKTRJean-Marie Eveillard 2008-03-31 Sold Out -0.01%$6.27 - $7.29
($6.8)
$ 15.69131%Sold Out0
NKTRJean-Marie Eveillard 2007-12-31 Add0.01%$5.57 - $8.27
($6.6)
$ 15.69138%Add 150%125,000
NKTRGeorge Soros 2007-12-31 Reduce-0.05%$5.57 - $8.27
($6.6)
$ 15.69138%Reduce -28.24%241,397
NKTRGeorge Soros 2007-09-30 Add0.02%$7.95 - $9.51
($8.7)
$ 15.6980%Add 26.87%336,397
NKTRJean-Marie Eveillard 2007-09-30 Buy $7.95 - $9.51
($8.7)
$ 15.6980%New holding, 50000 sh.50,000
NKTRGeorge Soros 2007-03-31 Reduce-0.13%$11.26 - $14.63
($12.9)
$ 15.6922%Reduce -45.45%364,897
NKTRGeorge Soros 2006-12-31 Add0.1%$14.38 - $16.84
($15.5)
$ 15.691%Add 30%668,897
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NKTR is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NKTR PRIMECAP Management 2014-09-3018,137,78614.120.23+14.76%
Premium Most recent portfolio changes are included for Premium Members only!


NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Labrucherie Gil MSVP & General Counsel 2014-12-01Sell120,000$17.02-7.81view
ROBIN HOWARD WPresident & CEO 2014-12-01Sell350,000$17.01-7.76view
ROBIN HOWARD WPresident & CEO 2014-11-25Sell600,000$15.252.89view
Labrucherie Gil MSVP & General Counsel 2014-11-24Sell10,500$15.044.32view
Lingnau LutzDirector 2014-11-24Sell15,000$15.024.46view
Labrucherie Gil MSVP & General Counsel 2014-11-03Sell9,900$13.7813.86view
KUEBLER CHRISTOPHER ADirector 2013-08-05Sell12,500$12.4126.43view
WHITFIELD ROY ADirector 2013-08-05Sell12,500$12.4126.43view
KUEBLER CHRISTOPHER ADirector 2012-09-27Sell12,500$10.6647.19view
WINGER DENNIS LDirector 2012-09-14Buy5,000$9.1870.92view

Press Releases about NKTR :

    Quarterly/Annual Reports about NKTR:

    News about NKTR:

    Articles On GuruFocus.com
    Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
    Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
    Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
    MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
    cooldecency99 note on NKTR May 01 2010 
    Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 

    More From Other Websites
    Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3... Dec 11 2014
    Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3... Dec 11 2014
    NEKTAR THERAPEUTICS Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Dec 11 2014
    Nektar/AstraZeneca's Moventig Gets EU Approval for OIC Dec 10 2014
    MOVENTIG® Approved In The European Union For Opioid-Induced Constipation Dec 09 2014
    MOVENTIG® Approved In The European Union For Opioid-Induced Constipation Dec 09 2014
    AstraZeneca, Nektar constipation drug wins European approval Dec 09 2014
    AstraZeneca, Nektar constipation drug wins European approval Dec 09 2014
    Biotech: When and Where to Sell Dec 03 2014
    Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII... Dec 01 2014
    Nektar Therapeutics (NKTR): Strong Industry, Solid Earnings Estimate Revisions Dec 01 2014
    Will Nektar Therapeutics (NKTR) Continue to Surge Higher? Nov 26 2014
    FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation Nov 24 2014
    Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a... Nov 20 2014
    Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a... Nov 20 2014
    Nektar Therapeutics (NKTR): An Off-the-Radar Potential Winner Nov 17 2014
    NEKTAR THERAPEUTICS Financials Nov 14 2014
    10-Q for Nektar Therapeutics Nov 10 2014
    Nektar Therapeutics Beats on Q3 Earnings and Revenues Nov 10 2014
    NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report Nov 07 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK